Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a neoadjuvant anti-PD-1 trial in patients with hepatocellular carcinoma (HCC), as well as additional samples collected from patients treated off-label, to explore correlates of response to ICB within T cell-rich tumors. We show that ICB response correlated with the clonal expansion of intratumoral CXCL13+CH25H+IL-21+PD-1+CD4+ T helper cells ("CXCL13+ T H") and Granzyme K+ PD-1+ effector-like CD8+ T cells, whereas terminally exhausted CD39 hi TOX hi PD-1 hi CD8+ T cells dominated in nonresponders. CD4+ and CD8+ T cell clones that expanded post-treatment were found in pretreatment biopsies. Notably, PD-1+TCF-1+ (Progenitor-exhausted) CD8+ T cells shared clones mainly with effector-like cells in responders or terminally exhausted cells in nonresponders, suggesting that local CD8+ T cell differentiation occurs upon ICB. We found that these Progenitor CD8+ T cells interact with CXCL13+ T H within cellular triads around dendritic cells enriched in maturation and regulatory molecules, or "mregDC". These results suggest that discrete intratumoral niches that include mregDC and CXCL13+ T H control the differentiation of tumor-specific Progenitor exhasuted CD8+ T cells following ICB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have shown that T cell infiltration in solid tumours is a predictive biomarker of response to ICIs69,82,100,111.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Deeper analyses revealed a robust correlation between pathological responses to neoadjuvant cemiplimab and the presence of intratumoural triads comprising regulatory dendritic cells, PD-1hi progenitor CD8+ T cells and CD4+ T cells expressing features of T follicular helper cells (such as CXCL13 and IL-21)82.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the trial of neoadjuvant cemiplimab82, the analysis of samples taken at the time of resection (after treatment) revealed that responsive tumours had high levels of T cell infiltration, although some non-responsive HCCs also had T cell enrichment (Fig. 2).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Each clinical trial mandated the assessment of a pathological response as part of their primary7 or secondary efficacy endpoints,9,11 and this assessment was prospectively collected and reported as part of the exploratory aims for all cohorts.12,18”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note, these niches were more frequent in tumours from responders even before undergoing treatment.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [82]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
Tversky, A. (1977) · Psychological Review · doi:10.1037/0033-295x.84.4.327 · Cited by 7,414
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cellpose: a generalist algorithm for cellular segmentation
Stringer, C., Wang, T., Michaelos, M., & Pachitariu, M. (2021) · Nature Methods · doi:10.1038/s41592-020-01018-x · Cited by 4,369
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Cited by
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
“Conversely, non-inflamed tumours have limited immune cell infiltration and low immune activity within the TME 71,78,82 .”
InfluentialSelf-citationTertiary lymphoid structures and B cells: An intratumoral immunity cycle
Fridman, W. H., Meylan, M., Pupier, G., Calvez, A., Hernandez, I., & Sautès-Fridman, C. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.009 · Cited by 326
Metadata
- Authors
- Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., Kim, J., Hamel, S., Buckup, M., Chang, C., Tabachnikova, A., Schwartz, H., Malissen, N., Lavin, Y., Soares-Schanoski, A., Giotti, B., Hegde, S., Ioannou, G., Gonzalez-Kozlova, E., Hennequin, C., Le Berichel, J., Zhao, Z., Ward, S. C., Fiel, I., Kou, B., Dobosz, M., Li, L., Adler, C., Ni, M., Wei, Y., Wang, W., Atwal, G. S., Kundu, K., Cygan, K. J., Tsankov, A. M., Rahman, A., Price, C., Fernandez, N., He, J., Gupta, N. T., Kim-Schulze, S., Gnjatic, S., Kenigsberg, E., Deering, R. P., Schwartz, M., Marron, T. U., Thurston, G., Kamphorst, A. O., & Merad, M.
- Affiliations
- Tisch Cancer Institute (US)
- Regeneron (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Schwartz, Myron
- Marron, Thomas U.
- Thurston, Gavin
- Kamphorst, Alice O.
- ORCID
- Magen, Assaf
- Hamon, Pauline
- Fiaschi, Nathalie
- Soong, Brian Y.
- Park, Matthew D.
- Mattiuz, Raphaël
- Troncoso, Leanna
- D’souza, Darwin
- Dawson, Travis
- Hamel, Steven
- Buckup, Mark
- Chang, Christie
- Tabachnikova, Alexandra
- Malissen, Nausicaa
- Lavin, Yonit
- Giotti, Bruno
- Hegde, Samarth
- Ioannou, Giorgio
- Gonzalez-Kozlova, Edgar
- Zhao, Zhen
- Ward, Stephen C.
- Ni, Min
- Wei, Yi
- Atwal, Gurinder S.
- Kundu, Kunal
- Cygan, Kamil J.
- Tsankov, Alexander M.
- Rahman, Adeeb
- He, Jiang
- Gupta, Namita T.
- Gnjatic, Sacha
- Kenigsberg, Ephraim
- Deering, Raquel P.
- Schwartz, Myron
- Marron, Thomas U.
- Thurston, Gavin
- Kamphorst, Alice O.
- Merad, Miriam
- Venue
- Nature Medicine
- Published
- 2023-06
- Volume
- 29
- Issue
- 6
- Pages
- 1389-1399
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11027932
- OpenAlex
- W4380786205
- Cited by
- 429
- References
- 75
- Citations by year
- 2026: 126 · 2025: 148 · 2024: 124 · 2023: 31
- FWCI
- 52.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- Pfizer
- Celgene
- Regeneron Pharmaceuticals
- National Institutes of Health (1r33ca263705-01, CA196521)
- Genentech
- EMD Serono
- National Cancer Institute (R33CA263705, K00CA223043, R01CA154947, R01CA257195, U24CA224319, P30CA196521, R01CA254104)
- National Institute of Allergy and Infectious Diseases (R01AI153363)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK124165)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R33HD105593)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- hepatocellular carcinoma, anti-PD-1 therapy, immune checkpoint blockade, dendritic cells, CD4+ T helper cells, CD8+ T cell differentiation, T cell exhaustion, granzyme K, T cell clonal expansion, tumor microenvironment, neoadjuvant immunotherapy
- MeSH terms
- Cell Differentiation, Dendritic Cells, T-Lymphocytes, Helper-Inducer, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41591-023-02345-0
- The paper
- Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., Kim, J., Hamel, S., Buckup, M., Chang, C., Tabachnikova, A., Schwartz, H., Malissen, N., Lavin, Y., Soares-Schanoski, A., . . . Merad, M. (2023). Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-023-02345-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.